Literature DB >> 8855977

Dysregulation of autocrine TGF-beta isoform production and ligand responses in human tumour-derived and Ha-ras-transfected keratinocytes and fibroblasts.

M S Fahey1, I C Paterson, A Stone, A J Collier, Y L Heung, M Davies, V Patel, E K Parkinson, S S Prime.   

Abstract

This study examined the autocrine production of TGF-beta 1, -beta 2 and -beta 3 in culture supernatants from tumour-derived (H series, n = 7; BICR series, n = 5), Ha-ras-transfected (n = 4) and normal (n = 2) human keratinocytes using a sandwich enzyme-linked immunosorbent assay (ELISA). Detection limits were 39.0 pg ml-1 for TGF-beta 1, 78.0 pg ml-1 for TGF-beta 2 and 1.9 ng ml-1 for TGF-beta 3. Tumour-derived oral keratinocytes predominantly produced less TGF-beta 1 than normal oral epithelial cells; the expression of endogenous TGF-beta 2 was variable. In keratinocytes containing mutant Ha-ras, TGF-beta 1 production was enhanced and TGF-beta 2 was undetectable. TGF-beta 3 mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR) but the protein was not detected in conditioned media, most probably because of the low detection limits of the ELISA for this isoform. Neutralisation experiments indicated that the latent TGF-beta peptide was secreted in keratinocyte conditioned medium. Seven tumour-derived keratinocyte cell lines (H series) and fibroblasts separated from normal (n = 1) and tumour-derived (n = 2) keratinocyte cultures were examined for their response to exogenous TGF-beta 1, -beta 2 and -beta 3. Six of seven tumour-derived keratinocyte cell lines were inhibited by TGF-beta 1 and TGF-beta 2 (-beta 1 > -beta 2); one cell line was refractory to both TGF-beta 1 and TGF-beta 2. Keratinocytes were inhibited (4 of 7), stimulated (1 of 7) or failed to respond (2 of 7) to TGF-beta 3, TGF-beta 1, -beta 2 and -beta 3 stimulated both normal and tumour-associated fibroblasts, but the tumour-associated fibroblasts showed less response to the ligands than their normal counterparts following prolonged treatment with each isoform. The results demonstrate variable autocrine production of TGF-beta isoforms by malignant keratinocytes, with loss of TGF-beta 1 generally associated with the tumour-derived phenotype and modification of endogenous isoform production dependent on the genetic background of the tumour cells. Further, the variable response of the tumour-derived keratinocytes and contiguous fibroblasts to the TGF-beta isoforms suggests that dysregulation of TGF-beta autocrine and paracrine networks are common characteristics of squamous epithelial malignancy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855977      PMCID: PMC2077118          DOI: 10.1038/bjc.1996.492

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Molecular characterization of transforming growth factor type beta 3.

Authors:  P ten Dijke; K K Iwata; M Thorikay; J Schwedes; A Stewart; C Pieler
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.

Authors:  D R Welch; A Fabra; M Nakajima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta.

Authors:  C L Arteaga; R J Coffey; T C Dugger; C M McCutchen; H L Moses; R M Lyons
Journal:  Cell Growth Differ       Date:  1990-08

4.  Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation.

Authors:  J A Pietenpol; J T Holt; R W Stein; H L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

5.  Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms.

Authors:  S Cheifetz; H Hernandez; M Laiho; P ten Dijke; K K Iwata; J Massagué
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

6.  Differential regulation of the expression of transforming growth factor-beta s 1 and 2 by retinoic acid, epidermal growth factor, and dexamethasone in NRK-49F and A549 cells.

Authors:  D Danielpour; K Y Kim; T S Winokur; M B Sporn
Journal:  J Cell Physiol       Date:  1991-08       Impact factor: 6.384

7.  Transforming growth factor beta 1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation.

Authors:  M M Hafez; D Infante; S Winawer; E Friedman
Journal:  Cell Growth Differ       Date:  1990-12

8.  Escape from transforming growth factor beta control and oncogene cooperation in skin tumor development.

Authors:  C Missero; S Ramon y Cajal; G P Dotto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

9.  Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene.

Authors:  A G Geiser; S J Kim; A B Roberts; M B Sporn
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

10.  Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts.

Authors:  A A Colletta; L M Wakefield; F V Howell; K E van Roozendaal; D Danielpour; S R Ebbs; M B Sporn; M Baum
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  5 in total

1.  Transforming growth factor-β enhances invasion and metastasis in Ras-transfected human malignant epidermal keratinocytes.

Authors:  Maria Davies; Stephen S Prime; John W Eveson; Nicky Price; Anu Ganapathy; Anita D'Mello; Ian C Paterson
Journal:  Int J Exp Pathol       Date:  2012-04       Impact factor: 1.925

2.  NOX5 mediates the crosstalk between tumor cells and cancer-associated fibroblasts via regulating cytokine network.

Authors:  Jie Chen; Yan Wang; Weimin Zhang; Di Zhao; Lingyuan Zhang; Jing Zhang; Jiawen Fan; Qimin Zhan
Journal:  Clin Transl Med       Date:  2021-08

3.  Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.

Authors:  S E Wang; Y Yu; T L Criswell; L M Debusk; P C Lin; R Zent; D H Johnson; X Ren; C L Arteaga
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

4.  Association between IL-10 polymorphisms (-1082A/G, -592A/C and -819T/C) and oral cancer risk.

Authors:  Yuehua You; Xinya Du; Mingwen Fan; Bin Wu; Chun Xie
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells.

Authors:  G J Thomas; I R Hart; P M Speight; J F Marshall
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.